Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 204

1.

Plasma Neurokinin A Levels Predict Survival in Well-Differentiated Neuroendocrine Tumors of the Small Bowel.

Woltering EA, Voros BA, Thiagarajan R, Beyer DT, Ramirez RA, Wang YZ, Mamikunian G, Boudreaux JP.

Pancreas. 2018 Aug;47(7):843-848. doi: 10.1097/MPA.0000000000001092.

PMID:
29939909
2.

Sustained Low Serum Substance P Levels in Non-Surviving Septic Patients.

Lorente L, Martín MM, Pérez-Cejas A, Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A.

Int J Mol Sci. 2017 Jul 15;18(7). pii: E1531. doi: 10.3390/ijms18071531.

3.

Substance P enhances proliferation and paracrine potential of adipose-derived stem cells in vitro.

Kim S, Piao J, Son Y, Hong HS.

Biochem Biophys Res Commun. 2017 Mar 25;485(1):131-137. doi: 10.1016/j.bbrc.2017.02.036. Epub 2017 Feb 10.

PMID:
28192115
4.

Serum substance P concentrations to predict oocyte maturation index and clinical pregnancy.

Sahin Y, Özkaya E, Kayatas Eser S, Kutlu T, Sanverdi I, Tunali G, Karateke A.

Gynecol Endocrinol. 2017 Mar;33(3):203-207. doi: 10.1080/09513590.2016.1254611. Epub 2016 Dec 2.

PMID:
27908224
5.

Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis.

Ardill JE, McCance DR, Stronge WV, Johnston BT.

Ann Clin Biochem. 2016 Mar;53(Pt 2):259-64. doi: 10.1177/0004563215592021. Epub 2015 Jun 2.

PMID:
26038607
6.

Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFNγ/IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis.

Vilisaar J, Kawabe K, Braitch M, Aram J, Furtun Y, Fahey AJ, Chopra M, Tanasescu R, Tighe PJ, Gran B, Pothoulakis C, Constantinescu CS.

J Neuroimmune Pharmacol. 2015 Sep;10(3):457-67. doi: 10.1007/s11481-015-9589-x. Epub 2015 Feb 18.

7.

Substance P is upregulated in the serum of patients with chronic spontaneous urticaria.

Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, Staubach P, Maurer M.

J Invest Dermatol. 2014 Nov;134(11):2833-2836. doi: 10.1038/jid.2014.226. Epub 2014 May 20. No abstract available.

8.

Substance P at the neuro-immune crosstalk in the modulation of inflammation, asthma and antimicrobial host defense.

Sun J, Bhatia M.

Inflamm Allergy Drug Targets. 2014;13(2):112-20. Review.

PMID:
24660773
9.

Increased substance P expression in the trochanteric bursa of patients with greater trochanteric pain syndrome.

Fearon AM, Twin J, Dahlstrom JE, Cook JL, Cormick W, Smith PN, Scott A.

Rheumatol Int. 2014 Oct;34(10):1441-8. doi: 10.1007/s00296-014-2957-7. Epub 2014 Feb 23.

10.

Evaluating the role of substance P in the growth of brain tumors.

Harford-Wright E, Lewis KM, Vink R, Ghabriel MN.

Neuroscience. 2014 Mar 7;261:85-94. doi: 10.1016/j.neuroscience.2013.12.027. Epub 2013 Dec 27.

PMID:
24374326
11.

Substance P in heart failure: the good and the bad.

Dehlin HM, Levick SP.

Int J Cardiol. 2014 Jan 1;170(3):270-7. doi: 10.1016/j.ijcard.2013.11.010. Epub 2013 Nov 12. Review.

12.

Copper(II) complexes of neuropeptide gamma with point mutations (S8,16A) products of metal-catalyzed oxidation.

Błaszak M, Jankowska E, Kowalik-Jankowska T.

J Inorg Biochem. 2013 Dec;129:62-70. doi: 10.1016/j.jinorgbio.2013.08.011. Epub 2013 Sep 5.

PMID:
24084156
13.

Substance P and intensity of pruritus in hemodialysis and peritoneal dialysis patients.

Snit M, Gawlik R, Łącka-Gaździk B, Kuźniewicz R, Dwornicki M, Owczarek A, Walaszczyk M, Grabiec P, Grzeszczak W.

Med Sci Monit. 2013 Sep 2;19:723-32. doi: 10.12659/MSM.889349.

14.

Substance P stimulates production of inflammatory cytokines in human disc cells.

Kepler CK, Markova DZ, Hilibrand AS, Vaccaro AR, Risbud MV, Albert TJ, Anderson DG.

Spine (Phila Pa 1976). 2013 Oct 1;38(21):E1291-9. doi: 10.1097/BRS.0b013e3182a42bc2.

PMID:
23873242
15.

Changes of substance P in the crevicular fluid in relation to orthodontic movement preliminary investigation.

Levrini L, Sacerdote P, Moretti S, Panzi S, Caprioglio A.

ScientificWorldJournal. 2013 Apr 23;2013:896874. doi: 10.1155/2013/896874. Print 2013.

16.

Investigation of serum substance P status in patients with chronic pruritic skin lesions due to sulfur mustard: a cross-sectional study.

Panahi Y, Taherzadeh ES, Davoudi SM, Sahebkar A, Ranjbar R.

Cutan Ocul Toxicol. 2013 Mar;32(1):4-8. doi: 10.3109/15569527.2012.686077. Epub 2012 Jun 11.

PMID:
22681041
17.

Cerebrospinal fluid substance P-like immunoreactivity correlates with aggression in personality disordered subjects.

Coccaro EF, Lee R, Owens MJ, Kinkead B, Nemeroff CB.

Biol Psychiatry. 2012 Aug 1;72(3):238-43. doi: 10.1016/j.biopsych.2012.02.023. Epub 2012 Mar 24.

PMID:
22449753
18.

The possible link between the elevated serum levels of neurokinin A and anti-ribosomal P protein antibodies in children with autism.

Mostafa GA, Al-Ayadhi LY.

J Neuroinflammation. 2011 Dec 21;8:180. doi: 10.1186/1742-2094-8-180.

19.

Validation of neurokinin a assays in the United States and Europe.

Mamikunian P, Ardill JE, O'Dorisio TM, Krutzik SR, Vinik AI, Go VL, Armstrong L, Mamikunian G, Woltering EA.

Pancreas. 2011 Oct;40(7):1000-5. doi: 10.1097/MPA.0b013e318232b6a2.

PMID:
21926539
20.

Developmental regulation of TAC1 in peptidergic-induced human mesenchymal stem cells: implication for spinal cord injury in zebrafish.

Patel N, Klassert TE, Greco SJ, Patel SA, Munoz JL, Reddy BY, Bryan M, Campbell N, Kokorina N, Sabaawy HE, Rameshwar P.

Stem Cells Dev. 2012 Jan 20;21(2):308-20. doi: 10.1089/scd.2011.0179. Epub 2011 Jul 26.

Supplemental Content

Support Center